There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aurinia Pharmaceuticals (AUPH) and Aslan Pharmaceuticals Ltd (ASLN) with bullish sentiments.
Aurinia Pharmaceuticals (AUPH)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $15. The company’s shares closed yesterday at $6.30.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.1% and a 36.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aurinia Pharmaceuticals with a $16.50 average price target, a 161.9% upside from current levels. In a report issued on January 22, Cantor Fitzgerald also maintained a Buy rating on the stock with a $18 price target.
See today’s analyst top recommended stocks >>
Aslan Pharmaceuticals Ltd (ASLN)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aslan Pharmaceuticals Ltd today and set a price target of $8.50. The company’s shares closed yesterday at $3.58, close to its 52-week low of $2.51.
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -15.9% and a 23.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aslan Pharmaceuticals Ltd with a $8.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
